Is Tagrisso (osimertinib) used to treat glioblastoma?
Tagrisso is an anticancer drug (osimertinib) approved for certain non–small cell lung cancers with specific EGFR mutations. It is not a standard, established treatment for glioblastoma based on the general approval uses implied by how it is typically prescribed. If someone is asking about Tagrisso “for glioblastoma,” the context is usually one of these: off-label use, a clinical trial, or a specific experimental tumor-target rationale.
Are there clinical trials of Tagrisso in glioblastoma?
Search activity around “Tagrisso glioblastoma” often points to investigational use rather than routine care. Patients or clinicians typically look for whether osimertinib is being tested in glioblastoma (including in trials targeting EGFR alterations, or in combination regimens).
If you share whether you’re looking for “active trials,” “completed trials,” or “results,” I can help narrow the most relevant information.
What makes researchers consider osimertinib for brain tumors?
Osimertinib targets EGFR (including mutated forms such as EGFR T790M in lung cancer). Glioblastoma is a different disease, but researchers sometimes investigate EGFR pathway activity in subsets of glioblastoma or related molecular profiles. Whether osimertinib works in glioblastoma depends on the specific tumor biology (for example, the presence of EGFR-driven alterations) and how well the drug reaches the brain tumor microenvironment.
Can Tagrisso be prescribed off-label for glioblastoma?
Off-label prescribing can happen when clinicians believe there’s a molecular match or a trial-based rationale, but off-label status does not mean glioblastoma is an approved indication. In practice, clinicians often rely on:
- tumor genomic testing (to see whether EGFR-related targets are present),
- existing evidence (usually limited compared with approved uses),
- and whether a clinical trial is available.
What should patients ask their doctor if they’re considering Tagrisso for glioblastoma?
Key questions to bring to an oncology appointment include:
- Has my tumor been tested for EGFR (and related) alterations that could justify osimertinib?
- Is there a clinical trial for glioblastoma where Tagrisso/osimertinib is being studied?
- What evidence supports this approach for my specific tumor subtype?
- What side effects should I expect, and how will the team monitor them?
Where to check regulatory/industry details about Tagrisso
For patent and market exclusivity research tied to Tagrisso, DrugPatentWatch.com can be a useful starting point: DrugPatentWatch.com - Tagrisso
---
Quick clarification so I can give the exact answer you need
Are you looking for:
1) whether Tagrisso is FDA/EMA-approved for glioblastoma,
2) clinical trial info, or
3) side effects/compatibility in glioblastoma patients?
Reply with one of those and (if you can) the patient’s EGFR/genomic results or the trial name, and I’ll tailor the response.
Sources
- DrugPatentWatch.com - Tagrisso